Use: Labeled indications
- Malignant Diseases: malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma…
- Minimal Change Nephrotic Syndrome in Pediatric Patients: biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Cyclophosphamide for Injection is an alkylating drug indicated for treatment of adults and pediatric patients with:
- Malignant Diseases: malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma (1.1)
- Minimal Change Nephrotic Syndrome in Pediatric Patients: biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy (1.2) Limitations of Use: The safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established. (1.2) 1.1 Malignant Diseases Cyclophosphamide for Injection is indicated for the treatment of adult and pediatric patients with: •malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma •multiple myeloma •leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) •mycosis fungoides (advanced disease) •neuroblastoma (disseminated disease) •adenocarcinoma of the ovary •retinoblastoma •carcinoma of the breast Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. 1.2 Minimal Change Nephrotic Syndrome in Pediatric Patients: Cyclophosphamide for Injection is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatric patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy. Limitations of Use: The safety and effectiveness of Cyclophosphamide for Injection for the treatment of nephrotic syndrome in adults or other renal disease has not been established.
Contraindications
- Severe hypersensitivity to cyclophosphamide
- Urinary outflow obstruction
Contraindications (US label) US FDA label
4 CONTRAINDICATIONS •Hypersensitivity Cyclophosphamide for Injection is contraindicated in patients who have a history of severe hypersensitivity reactions to cyclophosphamide, any of its metabolites, or to other components of the product. Anaphylactic reactions including death have been reported with cyclophosphamide. Cross-sensitivity with other alkylating agents can occur.
•Urinary Outflow Obstruction Cyclophosphamide Injection is contraindicated in patients with urinary outflow obstruction [see Warnings and Precautions (5.2)]. •Hypersensitivity to cyclophosphamide (4) •Urinary outflow obstruction (4)
Dosing: Adult
- Malignant diseases (IV): 40 to 50 mg/kg in divided doses over 2 to 5 days; or 10 to 15 mg/kg every 7 to 10 days; or 3 to 5 mg/kg twice weekly
- Malignant diseases (oral): 1 to 5 mg/kg/day
- Lupus nephritis, ANCA vasculitis: Glomerular disease regimens (lupus nephritis, ANCA vasculitis) use much lower IV doses than the oncology doses shown, with reductions for age and kidney function; follow the KDIGO 2024 lupus nephritis or ANCA-associated vasculitis guideline and a nephrologist.
- During or immediately after Cyclophosphamide for Injection administration, administer adequate amounts of fluid to reduce the risk of urinary tract toxicity (2.1). Malignant Diseases: Adult and Pediatric Patients (2.2)
- •Intravenous: Initial course for patients with no hematologic deficiency: 40 mg per kg to 50 mg per kg in divided doses over 2 to 5 days. Other regimens include 10 mg per kg to 15 mg per kg given every 7 to 10 days or 3 mg per kg to 5 mg per kg twice weekly. •Oral: 1 mg per kg per day to 5 mg per kg per day for both initial and maintenance dosing. Minimal Change Nephrotic Syndrome in Pediatric Patients (2.3)
- • Oral: 2 mg per kg daily for 8 to 12 weeks (maximum cumulative dose 168 mg per kg). • Treatment beyond 90 days increases the probability of sterility in males. (8.4)
2.1 Important Administration Instructions
2.1 Important Administration Instructions During or immediately after the administration of Cyclophosphamide for Injection, adequate amounts of fluid should be ingested or infused to force diuresis in order to reduce the risk of urinary tract toxicity. Therefore, Cyclophosphamide for Injection should be administered in the morning.
2.2 Recommended Dosage for Malignant Diseases Adults and Pediatric Patients Intravenous Use
2.2 Recommended Dosage for Malignant Diseases Adults and Pediatric Patients Intravenous Use When used as the only oncolytic drug therapy, the recommended dosage for the initial course of Cyclophosphamide for Injection for patients with no hematologic deficiency is 40 mg per kg to 50 mg per kg given intravenously in divided doses over a period of 2 to 5 days. Other intravenous regimens include 10 mg per kg to 15 mg per kg given every 7 to 10 days or 3 mg per kg to 5 mg per kg twice weekly.
Oral Use The recommended dosage for oral cyclophosphamide is 1 mg per kg per day to 5 mg per kg per day for both initial and maintenance dosing. Adjust the dosage of Cyclophosphamide for Injection based on the specific regimen administered, response to treatment, myelosuppression or other adverse reactions, and patient risk factors [see Warnings and Precautions (5)].
2.3 Recommended Dosage for Minimal Change Nephrotic Syndrome in Pediatric Patients
2.3 Recommended Dosage for Minimal Change Nephrotic Syndrome in Pediatric Patients The recommended dosage is 2 mg per kg orally once daily for 8 to 12 weeks (maximum cumulative dose 168 mg per kg) is recommended. Treatment beyond 90 days increases the probability of sterility in males [see Use in Specific Populations (8.4)
2.4 Preparation, Handling, and Administration
2.4 Preparation, Handling, and Administration Cyclophosphamide for Injection is a hazardous drug. Follow applicable special handling and disposal procedures1. Caution should be exercised when handling and preparing Cyclophosphamide for Injection. To minimize the risk of dermal exposure, always wear gloves when handling vials containingCyclophosphamide for Injection.
Cyclophosphamide for Injection Intravenous Administration Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use cyclophosphamide vials if there are signs of melting. Melted cyclophosphamide is a clear or yellowish viscous liquid usually found as a connected phase or in droplets in the affected vials.
Cyclophosphamide does not contain any antimicrobial preservative and thus care must be taken to assure the sterility of prepared solutions. Use aseptic technique. For Direct Intravenous Injection Reconstitute Cyclophosphamide with 0.9% Sodium Chloride Injection, USP only, using the volumes listed below in Table 1. Shake the vial vigorously to dissolve the drug completely.
Do not use Sterile Water for Injection, USP because it results in a hypotonic solution and should not be injected directly. Discard unused solution. Table 1: Reconstitution for Direct Intravenous Injection Strength Volume of 0.9% Sodium Chloride Injection, USP Cyclophosphamide Concentration 500 mg 25 mL 20 mg per mL 1 g 50 mL 2 g 100 mL For Intravenous Infusion Reconstitution of Cyclophosphamide: Reconstitute Cyclophosphamide using 0.9% Sodium Chloride Injection, USP or Sterile Water for Injection, USP with the volume of diluent listed below in Table 2.
Add the diluent to the vial and shake the vial vigorously to dissolve the drug completely. Discard unused solution. Table 2: Reconstitution in preparation for Intravenous Infusion Table 2: Reconstitution in preparation for Intravenous Infusion Strength Volume of Diluent Cyclophosphamide Concentration 500 mg 25 mL 20 mg per mL 1 g 50 mL 2 g 100 mL Dilution of Reconstituted Cyclophosphamide: Further dilute the reconstituted Cyclophosphamide solution to a minimum concentration of 2 mg per mL with any of the following diluents: 0.45% Sodium Chloride Injection, USP 5% Dextrose Injection, USP 5% Dextrose and 0.9% Sodium Chloride Injection, USP To reduce the likelihood of adverse reactions that appear to be administration rate-dependent (e.g., facial swelling, headache, nasal congestion, scalp burning), cyclophosphamide should be injected or infused very slowly.
Duration of the infusion also should be appropriate for the volume and type of carrier fluid to be infused. Storage of Reconstituted and Diluted Cyclophosphamide Solution: If not used immediately, for microbiological integrity, cyclophosphamide solutions should be stored as described in Table 3: Table 3: Storage of Cyclophosphamide Solutions Table 3: Storage of Cyclophosphamide Solutions Diluent Storage Room Temperature Refrigerated Reconstituted Solution (Without Further Dilution) 0.9% Sodium Chloride Injection, USP up to 24 hours Up to 6 days Sterile Water for Injection, USP Do not store; use immediately Diluted Solutions* 0.45% Sodium Chloride Injection, USP up to 24 hours Up to 6 days 5% Dextrose Injection, USP up to 24 hours up to 36 hours 5% Dextrose and 0.9% Sodium Chloride Injection, USP up to 24 hours up to 36 hours * Storage time is the total time cyclophosphamide is in solution including the time it is reconstituted in 0.9% Sterile Sodium Chloride Injection, USP or Sterile Water for Injection, USP.
Reconstituted Solution for Oral Administration Liquid preparations of cyclophosphamide for oral administration may be prepared by dissolving cyclophosphamide for injection in Aromatic Elixir, National Formulary (NF). Store preparations under refrigeration in glass containers and use within 14 days. See the prescribing information for cyclophosphamide for oral use for additional dosage information.
Dosing: Altered kidney function
Cyclophosphamide is an alkylating prodrug activated in the liver; 10% to 20% is excreted unchanged in urine, and metabolites cause hemorrhagic cystitis. In kidney impairment exposure rises (AUC up 38% at CrCl 25–50 and 77% at 10–24 mL/min), and the US label asks for toxicity monitoring in severe impairment but gives no numeric dose cut. It is dialyzable (about 37% removed in 4 hours), so the label advises a consistent interval between dose and dialysis. Glomerular disease regimens (lupus nephritis, ANCA vasculitis) use much lower IV doses than the oncology doses shown, with reductions for age and kidney function; follow the KDIGO 2024 lupus nephritis or ANCA-associated vasculitis guideline and a nephrologist.
Kidney function measure: Label uses CrCl (CLcr, mL/min): 25–50, 10–24, <10 on hemodialysis. No dose bands.
Show full dosing details
- CrCl ≥60 mL/min
- Usual regimen-specific dose (label); adjust for blood counts and toxicity. Hydrate well to protect the bladder.
- CrCl 30–59 mL/min
- No label dose change; exposure 38% higher at CrCl 25–50 (label). Monitor blood counts and bladder toxicity; adjust by response and adverse reactions.
- CrCl 15–29 mL/min
- Severe impairment (CrCl 10–24): exposure 77% higher; monitor for toxicity (label 8.6). No numeric dose cut in label; specialist dose decision.
- CrCl <15 mL/min (not on dialysis)
- Severe impairment: monitor closely for toxicity (label). No numeric dose cut in label; specialist dose decision.
- Hemodialysis (intermittent)
- Dialyzable: about 37% of a dose removed in a 4-hour hemodialysis (clearance about 104 mL/min). Keep a consistent interval between the dose and dialysis (label 8.6). Specialist dose decision.
- Peritoneal dialysis
- No PD data in label (label says removal varies with the dialysis system). Specialist input.
- CRRT
- No data in label. Specialist input.
- Dialyzable? Yes: dialysis clearance about 104 mL/min; mean 37% of the dose removed in a 4-hour hemodialysis; half-life 3.3 hours on dialysis versus 6.5 hours in uremic patients (label 12.3). Rapid hemodialysis is indicated in overdose (label 10).
- Monitoring Complete blood count before each dose; urinalysis for hematuria (hemorrhagic cystitis); serum creatinine; sodium (hyponatremia); signs of infection; pregnancy test before treatment.
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Usual regimen dose (label).
- eGFR 30–59
- No pediatric kidney data; label renal statements apply: monitor toxicity.
- eGFR 15–29
- Monitor for toxicity in severe impairment (label); specialist dose decision.
- eGFR <15 (not on dialysis)
- Monitor for toxicity; specialist dose decision.
- Hemodialysis (intermittent)
- Dialyzable; consistent dose–dialysis interval (label); specialist.
- Peritoneal dialysis
- No data; specialist.
- CRRT
- No data; specialist.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
8.6 Renal Impairment In patients with severe renal impairment, decreased renal excretion may result in increased plasma levels of cyclophosphamide and its metabolites, which may increase toxicity [see Clinical Pharmacology (12.3)]. Monitor patients with severe renal impairment (creatinine clearance (CLcr) =10 mL/min to 24 mL/min for signs and symptoms of toxicity.
Cyclophosphamide and its metabolites are dialyzable although there are probably quantitative differences depending upon the dialysis system. In patients requiring dialysis, consider using a consistent interval between cyclophosphamide administration and dialysis.
Renal Impairment Following one-hour intravenous infusion, cyclophosphamide AUC increased by 38% in patients with CLcr of 25 to 50 mL/min, by 77% in patients with CLcr of 10 to 24 mL/min and by 23% in the hemodialysis group (CLcr of < 10 mL/min) compared to the control group (CLcr≥ 80 mL/min). Cyclophosphamide is dialyzable.
Dialysis clearance averaged 104 mL/min, which is similar to the metabolic clearance of 95 mL/min for cyclophosphamide. A mean of 37% of the administered dose of cyclophosphamide was removed during a 4-hour hemodialysis period. The t½ was 3.3 hours in patients during hemodialysis, a 49% reduction compared to t½ of 6.5 hours in uremic patients.
Dosing: Hepatic impairment
8.7 Hepatic Impairment Patients with severe hepatic impairment have reduced conversion of cyclophosphamide to the active 4-hydroxyl metabolite, potentially reducing efficacy [see Clinical Pharmacology (12.3)]. Monitor patients with severe hepatic impairment (total bilirubin > 3 x ULN and any aspartate aminotransferase (AST)) for reduced effectiveness of cyclophosphamide.
US FDA labelDosing: Pediatric
- Approved ages
- Malignant diseases (adults and children); minimal change nephrotic syndrome in pediatric patients (oral) (label).
- Usual dose
- Minimal change nephrotic syndrome: 2 mg/kg orally once daily for 8 to 12 weeks (maximum cumulative dose 168 mg/kg). Malignancy: IV 40 to 50 mg/kg in divided doses over 2 to 5 days, or other regimens (label).
- Maximum dose
- Nephrotic syndrome: cumulative 168 mg/kg; treatment beyond 90 days raises the risk of male sterility.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
8.3 Females and Males of Reproductive Potential Cyclophosphamide for Injection can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)]. Pregnancy Testing Verify the pregnancy status of females of reproductive potential prior to the initiation of Cyclophosphamide for Injection. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with Cyclophosphamide for Injection and for up to 1 year after completion of therapy.
Males Based on findings in genetic toxicity and animal reproduction studies, advise male patients with female partners of reproductive potential to use effective contraception during treatment with Cyclophosphamide for Injection and for 4 months after completion of therapy [see Nonclinical Toxicology (13.1)]. Infertility Females Amenorrhea, transient or permanent, associated with decreased estrogen and increased gonadotropin secretion develops in a proportion of women treated with cyclophosphamide.
Affected patients generally resume regular menses within a few months after cessation of therapy. The risk of premature menopause with cyclophosphamide increases with age. Oligomenorrhea has also been reported in association with cyclophosphamide treatment. Animal data suggest an increased risk of failed pregnancy and malformations may persist after discontinuation of cyclophosphamide as long as oocytes/follicles exist that were exposed to cyclophosphamide during any of their maturation phases.
The exact duration of follicular development in humans is not known, but may be longer than 12 months [see Nonclinical Toxicology (13.1)]. Males Men treated with cyclophosphamide may develop oligospermia or azoospermia which are normally associated with increased gonadotropin but normal testosterone secretion.
8.4 Pediatric Use The safety and effectiveness of cyclophosphamide have been established in pediatric patients and information on this use is discussed throughout the labeling. Pre-pubescent females who receive cyclophosphamide generally develop secondary sexual characteristics normally and have regular menses. Ovarian fibrosis with apparently complete loss of germ cells after prolonged administration of cyclophosphamide in late pre-pubescence has been reported.
Females who received cyclophosphamide who have retained ovarian function after completing treatment are at increased risk of developing premature menopause. Pre-pubescent males who receive cyclophosphamide develop secondary sexual characteristics normally, but may have oligospermia or azoospermia and increased gonadotropin secretion.
Some degree of testicular atrophy may occur. Cyclophosphamide-induced azoospermia is reversible in some patients, though the reversibility may not occur for several years after cessation of therapy.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use There is insufficient data from clinical studies of cyclophosphamide available for patients 65 years of age and older to determine whether they respond differently than younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac functioning, and of concomitant disease or other drug therapy.
Administration
2.1 Important Administration Instructions During or immediately after the administration of Cyclophosphamide for Injection, adequate amounts of fluid should be ingested or infused to force diuresis in order to reduce the risk of urinary tract toxicity. Therefore, Cyclophosphamide for Injection should be administered in the morning.
2.4 Preparation, Handling, and Administration Cyclophosphamide for Injection is a hazardous drug. Follow applicable special handling and disposal procedures1. Caution should be exercised when handling and preparing Cyclophosphamide for Injection. To minimize the risk of dermal exposure, always wear gloves when handling vials containingCyclophosphamide for Injection. Cyclophosphamide for Injection Intravenous Administration Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use cyclophosphamide vials if there are signs of melting. Melted cyclophosphamide is a clear or yellowish viscous liquid usually found as a connected phase or in droplets in the affected vials. Cyclophosphamide does not contain any antimicrobial preservative and thus care must be taken to assure the sterility of prepared solutions. Use aseptic technique. For Direct Intravenous Injection Reconstitute Cyclophosphamide with 0.9% Sodium Chloride Injection, USP only, using the volumes listed below in Table 1. Shake the vial vigorously to dissolve the drug completely. Do not use Sterile Water for Injection, USP because it results in a hypotonic solution and should not be injected directly. Discard unused solution. Table 1: Reconstitution for Direct Intravenous Injection Strength Volume of 0.9% Sodium Chloride Injection, USP Cyclophosphamide Concentration 500 mg 25 mL 20 mg per mL 1 g 50 mL 2 g 100 mL For Intravenous Infusion Reconstitution of Cyclophosphamide: Reconstitute Cyclophosphamide using 0.9% Sodium Chloride Injection, USP or Sterile Water for Injection, USP with the volume of diluent listed below in Table 2. Add the diluent to the vial and shake the vial vigorously to dissolve the drug completely. Discard unused solution. Table 2: Reconstitution in preparation for Intravenous Infusion Table 2: Reconstitution in preparation for Intravenous Infusion Strength Volume of Diluent Cyclophosphamide Concentration 500 mg 25 mL 20 mg per mL 1 g 50 mL 2 g 100 mL Dilution of Reconstituted Cyclophosphamide: Further dilute the reconstituted Cyclophosphamide solution to a minimum concentration of 2 mg per mL with any of the following diluents: 0.45% Sodium Chloride Injection, USP 5% Dextrose Injection, USP 5% Dextrose and 0.9% Sodium Chloride Injection, USP To reduce the likelihood of adverse reactions that appear to be administration rate-dependent (e.g., facial swelling, headache, nasal congestion, scalp burning), cyclophosphamide should be injected or infused very slowly. Duration of the infusion also should be appropriate for the volume and type of carrier fluid to be infused. Storage of Reconstituted and Diluted Cyclophosphamide Solution: If not used immediately, for microbiological integrity, cyclophosphamide solutions should be stored as described in Table 3: Table 3: Storage of Cyclophosphamide Solutions Table 3: Storage of Cyclophosphamide Solutions Diluent Storage Room Temperature Refrigerated Reconstituted Solution (Without Further Dilution) 0.9% Sodium Chloride Injection, USP up to 24 hours Up to 6 days Sterile Water for Injection, USP Do not store; use immediately Diluted Solutions* 0.45% Sodium Chloride Injection, USP up to 24 hours Up to 6 days 5% Dextrose Injection, USP up to 24 hours up to 36 hours 5% Dextrose and 0.9% Sodium Chloride Injection, USP up to 24 hours up to 36 hours * Storage time is the total time cyclophosphamide is in solution including the time it is reconstituted in 0.9% Sterile Sodium Chloride Injection, USP or Sterile Water for Injection, USP. Reconstituted Solution for Oral Administration Liquid preparations of cyclophosphamide for oral administration may be prepared by dissolving cyclophosphamide for injection in Aromatic Elixir, National Formulary (NF). Store preparations under refrigeration in glass containers and use within 14 days. See the prescribing information for cyclophosphamide for oral use for additional dosage information.
US FDA labelDosage forms
Philippines
- Powder for injection: 1 g, 200 mg, 500 mg
- Powder for iv injection: 1 g, 200 mg, 500 mg
- Powder for i.v. injection: 1 g, 200 mg, 500 mg
- Lyophilized powder for injection: 1 g, 500 mg
- Powder for solution: 1000 mg
- Powder for solution for injection/infusion: 500 mg
Registered products in the Philippines
42 products registered with the Food and Drug Administration (FDA) Philippines list Cyclophosphamide as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products42
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
ClophosphasaphCyclophosphamide (as nonohydrate) | 200 mg Powder for Injection (I.V)10 mL-Capacity Type II Clear Glass Vial Sealed with Grey Butyl Rubber S topper and Aluminum Seal with PP Flip-Off Cap x 1's (Box of 1's) 15 mL-Capacity Type-II Clear Glass Vial Sealed with Grey Butyl Stopper and Aluminum Seal with PP Flip-Off Cap x 1's (Box of 1's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Nelpa Lifesciences, Inc | DRP-18091 | May 5, 2031 | |
Clophosphasaph-500Cyclophosphamide (As Monohydrate) | 500 mg Powder For Injection (I.V.)50 mL-Capacity Type-I Clear Glass Vial Sealed with Grey Bromobutyl Rubber Stopper and Aluminum Seal with Blue Flip-off Cap x 1's (Box of 1's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Nelpa Lifesciences, Inc. | DRP-18125 | May 7, 2031 | |
CoxanCyclophosphamide | 1 g Lyophilized Powder for Injection (IV)USP Type I Amber Glass Vial with Red Flip-Off Seal x 10 g (Box of 1's) ox of 1's) | RxVAT-exempt | Techno Drugs LimitedBangladesh | Bridgemark Marketing. | DR-XY42799 | Oct 11, 2028 | |
Cyclixine 1000Cyclophosphamide | 1 g Powder for Injection (IV)USP Type I Clear and Colorless Glass Vial (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Distribution Solutions Phils., IncImporter: Ambica International Corporation | DRP-5310-03 | May 28, 2029 | |
Cyclixine 500Cyclophosphamide | 500 mg Powder for IV InjectionUSP Type I flint, transparent glass vial Box of 1's | RxVAT-exempt | Getwell PharmaceuticalsIndia | Detoxicare Philippines, Inc.Importer: Ambica International Corporation | DRP-5335-04 | Jan 10, 2029 | |
Cyclo Spal-P 1000Cyclophosphamide | 1000 mg Powder for Solution (I.V.)50 mL clear moulded vial along with 20 mm fluorotic coated chlorobutyl rubber stopper and 20 mm aluminium flip-off seal red color button (Box of 1's) | RxVAT-exempt | SP Accure Labs Pvt. Ltd.India | Hexagon Pharmaceuticals | DRP - 15356 | Jun 28, 2029 | |
Cyclo Spal-P 500Cyclophosphamide. | 500 mg Powder for Solution for Injection/Infusion50 mL clear moulded vial along with 20 mm fluorotec coated chlorobutyl rubber stopper and 20 mm aluminium flip-off seal-Red color button | RxVAT-exempt | SP Accure Labs Pvt. Ltd.India | Hexagon Pharmaceuticals | DRP - 15357 | Jun 28, 2029 | |
CyclocelCyclophosphamide | 1 g Powder for Injection (I.V.)USP Type I clear glass vial x 50 mL (Box of 1's) | RxVAT-exempt | Celon Laboratories Pvt. Ltd.India | I.E Medica Inc. | DRP-6019 | Feb 23, 2030 | |
CYCLOCELCyclophosphamide | 200mg Powder for Injection (I.V)USP Type I clear glass vial x 10 mL Box of 1's | RxVAT-exempt | CELON LABORATORIES Pvt. Ltd.India | I.E MEDICA INC. | DRP-6018 | Feb 23, 2030 | |
CyclocelCyclophosphamide | 500 mg Powder for Injection (I.V)USP Type I clear glass vial x 30mL (Box of 1's) | RxVAT-exempt | CELON LABORATORIES Pvt. Ltd.India | I.E MEDICA INC. | DRP-6020 | Feb 23, 2030 | |
CyclophosCyclophosphamide | 200 mg Powder for IV InjectionUSP Type I Clear, Colorless Glass Vial x 15 mL (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Diafarm Inc.Importer: Ambica International Corporation | DRP-5167-02 | Feb 11, 2029 | |
CyclophosCyclophosphamide | 500 mg Powder for IV InjectionUSP Type I Flint, Transparent Glass Vial (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Qualimed Pharma Inc.Importer: Ambica International Corporation | DRP-5335-06 | Jan 10, 2029 | |
CyphocareCyclophosphamide | 1 g Powder for Injection (IV)USP Type I Clear and Colorless Glass Vial (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Pharma 518, Inc.Importer: Ambica International Corporation | DRP-5310-06 | May 28, 2029 | |
CyphocareCyclophosphamide | 500 mg Powder for IV InjectionUSP Type I flint, transparent glass vial (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Pharma 518, Inc.Importer: Ambica International Corporation | DRP-5335-05 | Jan 10, 2029 | |
Cyphos-1Cyclophosphamide | 1 g Powder for Injection (IV)USP Type I Clear Colorless Glass Vial (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Macropharma CorporationImporter: Ambica International Corporation | DRP-5310 | May 28, 2029 | |
Cyphos-200Cyclophosphamide | 200 mg Powder for IV InjectionUSP Type I Clear, Colorless Glass Vial x 15 mL (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Ambica International Corporation | DRP-5167 | Feb 11, 2029 | |
Cyphos-500Cyclophosphamide | 500 mg Powder for IV InjectionUSP Type I flint, transparent glass vial (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Macropharma CorporationImporter: Ambica International Corporation | DRP-5335 | Jan 10, 2029 | |
CytoaceCyclophosphamide | 1 g Powder for IV InjectionUSP Type I Clear and Colorless Glass Vial (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Genace Pharma DistributorImporter: Ambica International Corporation | DRP-5310-02 | May 28, 2029 | |
CytoaceCyclophosphamide | 500 mg Powder for I.V. InjectionUSP Type I flint, transparent glass vial (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Genace Pharma DistributorImporter: Ambica International Corporation | DRP-5335-02 | Jan 10, 2029 | |
FuzfaCyclophosphamide | 500 mg Powder for IV InjectionUSP Type I flint, transparent glass vial (Box of 1's) | RxVAT-exempt | Getwell Pharma India Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-5335-09 | Jan 10, 2029 | |
Glotoxan-1Cyclophosphamide | 1 g Powder for IV InjectionUSP Type I Clear and Colorless Glass Vial Box of 1’s | RxVAT-exempt | Getwell PharmaceuticalsIndia | Globo Asiatico Enterprises, Inc.Importer: Ambica International Corporation | DRP-5310-01 | May 28, 2029 | |
Glotoxan-200Cyclophosphamide | 200 mg Powder for IV InjectionUSP Type I Clear, Colorless Glass Vial x 15 mL Box of 1’s | RxVAT-exempt | Getwell PharmaceuticalsIndia | Globo Asiatico Enterprise, Inc.Importer: Ambica International Corporation | DRP-5167-01 | Feb 11, 2029 | |
Glotoxan-500Cyclophosphamide | 500 mg Powder for I.V. InjectionUSP Type I Flint, Transparent Glass Vial (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Globo Asiatico Enterprises, Inc.Importer: Ambica International Corporation | DRP-5335-01 | Jan 10, 2029 | |
NeoncoCyclophosphamide | 1g Powder for Injection (I.V.)100 mL USP Type I clear glass vial with grey bromo butyl rubber stopper and 32 mm Light Green Aluminum. Flip off seal (Box of 1's) | RxVAT-exempt | Shilpa Medicare Limited Unit 4 Pharmaceutical Formulations SezIndia | Endure Medical, Inc. | DR-XY48860 | Aug 1, 2029 | |
Nuphos-1000Cyclophosphamide | 1 g Powder for Injection50 mL USP Type III Amber Glass Vial (Box of 1's) | RxVAT-exempt | Zee Laboratories LimitedIndia | Eon Pharmatek, IncImporter: Eon Pharmatek, Inc. | DR-XY42611 | Sep 12, 2028 | |
Nuphos-1000Cyclophosphamide | 1 g Powder for Injection50 mL USP Type III Amber Glass Vial (Box of 1's) | RxVAT-exempt | Zee Laboratories LimitedIndia | Eon Pharmatek, Inc. | DRP-15571 | Sep 12, 2028 | |
Nuphos-500Cyclophosphamide | 500 mg Powder for Injection (I.V.)30 mL USP Type III Amber Glass Vial (Box of 1's) | RxVAT-exempt | ZEE LABORATORIES LIMITEDIndia | EON PHARMATEK, INC | DR-XY42517 | Sep 2, 2028 | |
Nuphos-500Cyclophosphamide | 500 mg Powder for Injection (I.V.)30 mL USP Type III Amber Glass Vial (Box of 1's) | RxVAT-exempt | Zee Laboratories LimitedIndia | Eon Pharmatek Inc. | DRP-15576 | Sep 2, 2028 | |
OncocylCyclophosphamide | 1 g Lyophilized Powder for Injection (IV)50 mL-capacity USP Type I clear and colorless glass vial with bromobutyl rubber stopper and blue-colored aluminum flip-off seal (Box of l's) | RxVAT-exempt | Kwality Pharmaceuticals LimitedIndia | Pharma-Surrey International Inc. | DRP-17303 | Nov 13, 2030 | |
Phosphabene 200Cyclophosphamide | 200 mg Powder for Injection (I.V)USP Type I clear glass vial x 10 mL (Box of 1's) | RxVAT-exempt | Celon Laboratories Pvt. Ltd.India | Medethix Inc.Importer: I.E Medica Inc. | DRP-6018-01 | Feb 23, 2030 | |
Phosphabene 500Cyclophosphamide | 500 mg Powder for Injection (I.V)USP Type I clear glass vial x 30mL (Box of 1's) | RxVAT-exempt | Celon Laboratories Pvt. Ltd.India | Medethix Inc.Importer: I.E Medica Inc. | DRP-6020-01 | Feb 23, 2030 | |
PhosphaxilCyclophosphamide | 1 g Powder for IV Injection (IV)USP Type I Clear and Colorless Glass Vial Box of 1’s | RxVAT-exempt | Getwell PharmaceuticalsIndia | Globo Asiatico Enterprises, Inc.Importer: Ambica International Corporation | DRP-5310-05 | May 28, 2029 | |
PhosphaxilCyclophosphamide (as monohydrate) | 200 mg Powder for IV InjectionUSP Type I Clear, Colorless Glass Vial x 15 mL (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Globo Asiatico Enterprise, Inc.Importer: Ambica International Corporation | DRP-5167-03 | Feb 11, 2029 | |
PhosphaxilCyclophosphamide | 500 mg Powder for IV InjectionUSP Type I Flint, Transparent Glass Vial (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Globo Asiatico Enterprises, Inc.Importer: Ambica International Corporation | DRP-5335-07 | Jan 10, 2029 | |
SaphclophamideCyclophosphamide (As Monohydrate) | 1 g Powder For Injection (I.V)Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x l's (Box of l's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11219 | Feb 15, 2027 | |
SyklogetCyclophosphamide | 1 g Powder for Injection (IV)USP Type I Clear and Colorless Glass Vial (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | 2MG IncorporatedImporter: Ambica International Corporation | DRP-5310-07 | May 28, 2029 | |
SyklogetCyclophosphamide | 500 mg Powder for I.V. InjectionUSP Type I flint, transparent glass vial Box of 1’s | RxVAT-exempt | Getwell PharmaceuticalsIndia | 2MG IncorporatedImporter: Ambica International Corporation | DRP-5335-08 | Jan 10, 2029 | |
SykloGet -1000Cyclophosphamide (as monohydrate) | 1g Lyophilized Powder for Injection (IV)50mL-capacity Type I Clear Tubular Glass Vial Sealed with Gray Butyl Rubber Stopper and Aluminum Seal with Red PP Flip-Off Cap x 1's (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | 2MG Incorporated | DRP-16940 | Aug 28, 2030 | |
SykloGet -500Cyclophosphamide (as monohydrate) | 500 mg Lyophilized Powder for Injection (IV)30mL-capacity Type I Clear Tubular Glass Vial Sealed Bubular with Gray Butyl Rubber Stopper and Aluminum Seal with Red PP Flip-Off Cap x 1's (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | 2MG Incorporated | DRP-16941 | Aug 28, 2030 | |
ZycloxCyclophosphamide (as monohydrate) | 1 g Powder for I.V. Injection100 mL-capacity Type I clear glass vial, with chlorobutyl rubber stopper, aluminum seal and green flip-off cap (Box of 1's) | RxVAT-exempt | Sichuan Huiyu Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-17407 | Dec 12, 2031 | |
ZycloxCyclophosphamide (as monohydrate) | 200 mg Powder for I.V. Injection20 mL-capacity Type I clear glass vial, with chlorobutyl rubber stopper, aluminum seal and blue flip-off cap (Box of 1's) | RxVAT-exempt | Sichuan Huiyu Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-17409 | Dec 12, 2031 | |
ZycloxCyclophosphamide (as monohydrate) | 500 mg Powder for I.V. Injection50 mL-capacity Type I clear glass vial, with chlorobutyl rubber stopper, aluminum seal and red flip-off cap (Box of 1's) | RxVAT-exempt | Sichuan Huiyu Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-17408 | Dec 12, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Cyclophosphamide for Injection, USP (lyophilized powder) is a sterile white cake available in single-dose vials •500 mg •1 g •2 g • For Injection, lyophilized powder: 500 mg, 1 g, and 2 g
Warnings/Precautions
- • Myelosuppression, Immunosuppression, Bone Marrow Failure and Infections: Severe immunosuppression may lead to serious and sometimes fatal infections. Close hematological monitoring is required. (5.1)
- • Urinary Tract and Renal Toxicity: Hemorrhagic cystitis, pyelitis, ureteritis, and hematuria can occur. Urotoxicity can be fatal. Exclude or correct any urinary tract obstructions prior to treatment. (5.2)
- • Cardiotoxicity: Myocarditis, myopericarditis, pericardial effusion, arrythmias and congestive heart failure, which may be fatal, have been reported. Monitor patients, especially those with risk factors for cardiotoxicity or pre-existing cardiac disease. (5.3)
- • Pulmonary Toxicity: Pneumonitis, pulmonary fibrosis and pulmonary veno-occlusive disease leading to respiratory failure may occur. Monitor patients for signs and symptoms of pulmonary toxicity. (5.4)
- • Secondary malignancies (5.5)
- • Veno-occlusive Liver Disease: Fatal outcome can occur. (5.6)
- • Embryo-Fetal Toxicity: Can cause fetal harm. Advise patients of reproductive potential of the potential risk to a fetus and to use effective contraception. (5.7, 8.1, 8.3)
5.1 Myelosuppression, Immunosuppression, Bone Marrow Failure and Infections
5.1 Myelosuppression, Immunosuppression, Bone Marrow Failure and Infections Cyclophosphamide can cause myelosuppression (leukopenia, neutropenia, thrombocytopenia and anemia), bone marrow failure, and severe immunosuppression which may lead to serious and sometimes fatal infections, including sepsis and septic shock. Latent infections can be reactivated [see Adverse Reactions (6.2)].
Antimicrobial prophylaxis may be indicated in certain cases of neutropenia at the discretion of the managing physician. In case of neutropenic fever, antibiotic therapy is indicated. Antimycotics and/or antivirals may also be indicated. Monitoring of complete blood counts is essential during cyclophosphamide treatment so that the dose can be adjusted, if needed.
Cyclophosphamide should not be administered to patients with neutrophils ≤1,500/mm3 and platelets < 50,000/mm3. Cyclophosphamide treatment may not be indicated, or should be interrupted, or the dose reduced, in patients who have or who develop a serious infection. G-CSF may be administered to reduce the risks of neutropenia complications associated with cyclophosphamide use.
Primary and secondary prophylaxis with G-CSF should be considered in all patients considered to be at increased risk for neutropenia complications. The nadirs of the reduction in leukocyte count and thrombocyte count are usually reached in weeks 1 and 2 of treatment. Peripheral blood cell counts are expected to normalize after approximately 20 days.
Bone marrow failure has been reported. Severe myelosuppression may be expected particularly in patients pretreated with and/or receiving concomitant chemotherapy and/or radiation therapy.
5.2 Urinary Tract and Renal Toxicity
5.2 Urinary Tract and Renal Toxicity Hemorrhagic cystitis, pyelitis, ureteritis, and hematuria have been reported with cyclophosphamide. Medical and/or surgical supportive treatment may be required to treat protracted cases of severe hemorrhagic cystitis. Discontinue cyclophosphamide therapy in case of severe hemorrhagic cystitis.
Urotoxicity (bladder ulceration, necrosis, fibrosis, contracture and secondary cancer) may require interruption of cyclophosphamide treatment or cystectomy. Urotoxicity can be fatal. Urotoxicity can occur with short-term or long-term use of cyclophosphamide. Before starting treatment, exclude or correct any urinary tract obstructions [see Contraindications (4)].
Urinary sediment should be checked regularly for the presence of erythrocytes and other signs of urotoxicity and/or nephrotoxicity. Cyclophosphamide should be used with caution, if at all, in patients with active urinary tract infections. Aggressive hydration with forced diuresis and frequent bladder emptying can reduce the frequency and severity of bladder toxicity.
Mesna has been used to prevent severe bladder toxicity.
5.3 Cardiotoxicity
5.3 Cardiotoxicity Myocarditis, myopericarditis, pericardial effusion including cardiac tamponade, and congestive heart failure, which may be fatal, have been reported with cyclophosphamide therapy. Supraventricular arrhythmias (including atrial fibrillation and flutter) and ventricular arrhythmias (including severe QT prolongation associated with ventricular tachyarrhythmia) have been reported after treatment with regimens that included cyclophosphamide.
The risk of cardiotoxicity may be increased with high doses of cyclophosphamide, in patients with advanced age, and in patients with previous radiation treatment to the cardiac region and/or previous or concomitant treatment with other cardiotoxic agents. Particular caution is necessary in patients with risk factors for cardiotoxicity and in patients with pre-existing cardiac disease.
Monitor patients with risk factors for cardiotoxicity and with pre-existing cardiac disease.
5.4 Pulmonary Toxicity
5.4 Pulmonary Toxicity Pneumonitis, pulmonary fibrosis, pulmonary veno-occlusive disease and other forms of pulmonary toxicity leading to respiratory failure have been reported during and following treatment with cyclophosphamide. Late onset pneumonitis (greater than 6 months after start of cyclophosphamide) appears to be associated with increased mortality.
Pneumonitis may develop years after treatment with cyclophosphamide. Monitor patients for signs and symptoms of pulmonary toxicity.
5.5 Secondary Malignancies
5.5 Secondary Malignancies Cyclophosphamide is genotoxic [see Nonclinical Toxicology (13.1)]. Secondary malignancies (urinary tract cancer, myelodysplasia, acute leukemias, lymphomas, thyroid cancer, and sarcomas) have been reported in patients treated with cyclophosphamide-containing regimens. The risk of bladder cancer may be reduced by prevention of hemorrhagic cystitis.
5.6 Veno-occlusive Liver Disease
5.6 Veno-occlusive Liver Disease Veno-occlusive liver disease (VOD) including fatal outcome has been reported in patients receiving cyclophosphamide-containing regimens. A cytoreductive regimen in preparation for bone marrow transplantation that consists of cyclophosphamide in combination with whole-body irradiation, busulfan, or other agents has been identified as a major risk factor.
VOD has also been reported to develop gradually in patients receiving long-term low-dose immunosuppressive doses of cyclophosphamide. Other risk factors predisposing to the development of VOD include preexisting disturbances of hepatic function, previous radiation therapy of the abdomen, and a low performance status.
5.7 Embryo-Fetal Toxicity
5.7 Embryo-Fetal Toxicity Based on its mechanism of action and published reports of effects in pregnant patients or animals, Cyclophosphamide for Injection can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1), Clinical Pharmacology (12.1), and Nonclinical Toxicology (13.1)]. Exposure to cyclophosphamide during pregnancy may cause birth defects, miscarriage, fetal growth retardation, and fetotoxic effects in the newborn.
Cyclophosphamide is teratogenic and embryo-fetal toxic in mice, rats, rabbits and monkeys. Advise pregnant women and females of reproductive potential of the potential risk to a fetus [see Use in Specific Populations (8.1)]. Advise females of reproductive potential to use effective contraception during treatment with Cyclophosphamide for Injection and for up to 1 year after completion of therapy.
Advise male patients with female partners of reproductive potential to use effective contraception during treatment with Cyclophosphamide for Injection and for 4 months after completion of therapy [see Use in Specific Populations (8.1, 8.3)].
5.8 Infertility
5.8 Infertility Male and female reproductive function and fertility may be impaired in patients being treated with Cyclophosphamide for Injection. Cyclophosphamide interferes with oogenesis and spermatogenesis. It may cause sterility in both sexes. Development of sterility appears to depend on the dose of cyclophosphamide, duration of therapy, and the state of gonadal function at the time of treatment.
Cyclophosphamide-induced sterility may be irreversible in some patients. Advise patients on the potential risks for infertility [see Use in Specific Populations (8.3, 8.4)]
5.9 Impairment of Wound Healing
5.9 Impairment of Wound Healing Cyclophosphamide may interfere with normal wound healing.
5.10 Hyponatremia
5.10 Hyponatremia Hyponatremia associated with increased total body water, acute water intoxication, and a syndrome resembling SIADH (syndrome of inappropriate secretion of antidiuretic hormone), which may be fatal, has been reported.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Protease inhibitors | Adjust or monitor | More cytotoxic metabolites: infection, neutropenia, mucositis (label). | Monitor for toxicity. |
| Other myelosuppressive, nephrotoxic, cardiotoxic or hepatotoxic drugs; radiation | Adjust or monitor | Additive toxicity (label). | Monitor. |
| Metronidazole | Adjust or monitor | Acute encephalopathy reported (label). | Monitor. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewed7.1 Effect of Other Drugs on Cyclophosphamide Exposure Protease Inhibitors
7.1 Effect of Other Drugs on Cyclophosphamide Exposure Protease Inhibitors Concomitant use of protease inhibitors may increase the concentration of cytotoxic metabolites and may enhance the toxicities of cyclophosphamide, including higher incidence of infections, neutropenia, and mucositis. Monitor for increased toxicities in patients receiving protease inhibitors.
7.2 Drugs That Potentiate
7.2 Drugs That Potentiate Cyclophosphamide Toxicities Radiation therapy or drugs with similar toxicities to Cyclophosphamide for Injection can potentiate toxicities for cyclophosphamide. Monitor for increased toxicities in patients receiving radiation therapy or drugs known to cause:
- Myelosuppression and/or immunosuppression [see Warnings and Precautions (5.1)]
- Nephrotoxicity including hemorrhagic cystitis [see Warnings and Precautions (5.2)]
- Cardiotoxicity [see Warnings and Precautions (5.3)]
- Pulmonary toxicity [see Warnings and Precautions (5.4)]
- Secondary malignancies [see Warnings and Precautions (5.5)]
- Hepatotoxicity including liver necrosis and VOD [see Warnings and Precautions (5.6)]
7.3 Effect of Cyclophosphamide on Other Drugs Metronidazole
7.3 Effect of Cyclophosphamide on Other Drugs Metronidazole Acute encephalopathy has been reported in a patient receiving cyclophosphamide and metronidazole. Monitor for neurologic toxicities in patients receiving metronidazole. Tamoxifen Concomitant use of tamoxifen and a cyclophosphamide-containing chemotherapy regimen may increase the risk of thromboembolic complications.
Monitor for signs and symptoms of thromboembolic events in patients receiving tamoxifen. Coumarins Both increased and decreased warfarin effect have been reported in patients receiving warfarin and cyclophosphamide. Monitor anticoagulant activity closely in patients receiving warfarin or other coumarins. Cyclosporine Concomitant administration of cyclophosphamide may decrease serum concentrations of cyclosporine.
This interaction may result in an increased incidence of graft-versus-host disease. Monitor for signs and symptoms of graft-versus-host disease in patients receiving cyclosporine. Depolarizing muscle relaxants If a patient has been treated with cyclophosphamide within 10 days of general anesthesia, alert the anesthesiologist.
Cyclophosphamide causes a marked and persistent inhibition of cholinesterase activity. Prolonged apnea may occur with concurrent depolarizing muscle relaxants (e.g., succinylcholine).
7.1 Effect of Other Drugs on Cyclophosphamide Exposure Protease Inhibitors
7.1 Effect of Other Drugs on Cyclophosphamide Exposure Protease Inhibitors Concomitant use of protease inhibitors may increase the concentration of cytotoxic metabolites and may enhance the toxicities of cyclophosphamide, including higher incidence of infections, neutropenia, and mucositis. Monitor for increased toxicities in patients receiving protease inhibitors.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Metabolism Cyclophosphamide is metabolized by cytochrome P450s including CYP2A6, 2B6, 3A, 2C9, and 2C19.
Adverse reactions
Common
- Neutropenia, febrile neutropenia, fever
- Alopecia
- Nausea, vomiting, diarrhea
Serious
- Myelosuppression and serious infections
- Hemorrhagic cystitis, urotoxicity
- Cardiotoxicity
- Pulmonary toxicity
- Secondary malignancies
- Veno-occlusive liver disease
- Hyponatremia
- Embryo-fetal toxicity; infertility
Adverse reactions (US label) US FDA label
6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail in other sections of the labeling. Hypersensitivity [see Contraindications (4)] Myelosuppression, Immunosuppression, Bone Marrow Failure, and Infections [see Warnings and Precautions (5.1)] Urinary Tract and Renal Toxicity [see Warnings and Precautions (5.2)] Cardiotoxicity [see Warnings and Precautions (5.3)] Pulmonary Toxicity [see Warnings and Precautions (5.4)] Secondary Malignancies [see Warnings and Precautions (5.5)] Veno-occlusive Liver Disease [see Warnings and Precautions (5.6)] Infertility [see Warnings and Precautions (5.8) and Use in Specific Populations (8.3, 8.4)] Impaired Wound Healing [see Warnings and Precautions (5.9)] Hyponatremia [see Warnings and Precautions (5.10)] Adverse reactions reported most often include neutropenia, febrile neutropenia, fever, alopecia, nausea, vomiting, and diarrhea.
(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Hisun Pharmaceuticals USA, Inc. at 1-855-554-4786 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials and Postmarketing Experience The following adverse reactions associated with the use of cyclophosphamide were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The most common adverse reactions were neutropenia, febrile neutropenia, fever, alopecia, nausea, vomiting, and diarrhea. Cardiac: cardiac arrest, ventricular fibrillation, ventricular tachycardia, cardiogenic shock, pericardial effusion (progressing to cardiac tamponade), myocardial hemorrhage, myocardial infarction, cardiac failure (including fatal outcomes), cardiomyopathy, myocarditis, pericarditis, carditis, atrial fibrillation, supraventricular arrhythmia, ventricular arrhythmia, bradycardia, tachycardia, palpitations, QT prolongation.
Congenital, Familial and Genetic: intra-uterine death, fetal malformation, fetal growth retardation, fetal toxicity (including myelosuppression, gastroenteritis). Ear and Labyrinth: deafness, hearing impaired, tinnitus. Endocrine: water intoxication. Eye: visual impairment, conjunctivitis, lacrimation. Gastrointestinal: gastrointestinal hemorrhage, acute pancreatitis, colitis, enteritis, cecitis, stomatitis, constipation, parotid gland inflammation, nausea, vomiting, diarrhea.
General Disorders and Administrative Site Conditions: multiorgan failure, general physical deterioration, influenza-like illness, injection/infusion site reactions (thrombosis, necrosis, phlebitis, inflammation, pain, swelling, erythema), pyrexia, edema, chest pain, mucosal inflammation, asthenia, pain, chills, fatigue, malaise, headache, febrile neutropenia. Hematologic: myelosuppression, bone marrow failure, disseminated intravascular coagulation and hemolytic uremic syndrome (with thrombotic microangiopathy).
Hepatic: veno-occlusive liver disease, cholestatic hepatitis, cytolytic hepatitis, hepatitis, cholestasis; hepatotoxicity with hepatic failure, hepatic encephalopathy, ascites, hepatomegaly, blood bilirubin increased, hepatic function abnormal, hepatic enzymes increased. Immune: immunosuppression, anaphylactic shock and hypersensitivity reaction.
Infections: The following manifestations have been associated with myelosuppression and immunosuppression caused by cyclophosphamide: increased risk for and severity of pneumonias (including fatal outcomes), other bacterial, fungal, viral, protozoal and, parasitic infections; reactivation of latent infections, (including viral hepatitis, tuberculosis), pneumocystis jiroveci, herpes zoster, strongyloides, sepsis and septic shock. Investigations: blood lactate dehydrogenase increased, C-reactive protein increased.
Metabolism and Nutrition: hyponatremia, fluid retention, blood glucose increased, blood glucose decreased. Musculoskeletal and Connective Tissue: rhabdomyolysis, scleroderma, muscle spasms, myalgia, arthralgia. Neoplasms: acute leukemia, myelodysplastic syndrome, lymphoma, sarcomas, renal cell carcinoma, renal pelvis cancer, bladder cancer, ureteric cancer, thyroid cancer.
Nervous System: encephalopathy, convulsion, dizziness, neurotoxicity has been reported and manifested as reversible posterior leukoencephalopathy syndrome, myelopathy, peripheral neuropathy, polyneuropathy, neuralgia, dysesthesia, hypoesthesia, paresthesia, tremor, dysgeusia, hypogeusia, parosmia. Pregnancy: premature labor.
Psychiatric: confusional state. Renal and Urinary: renal failure, renal tubular disorder, renal impairment, nephropathy toxic, hemorrhagic cystitis, bladder necrosis, cystitis ulcerative, bladder contracture, hematuria, nephrogenic diabetes insipidus, atypical urinary bladder epithelial cells. Reproductive System: infertility, ovarian failure, ovarian disorder, amenorrhea, oligomenorrhea, testicular atrophy, azoospermia, oligospermia.
Respiratory: pulmonary veno-occlusive disease, acute respiratory distress syndrome, interstitial lung disease as manifested by respiratory failure (including fatal outcomes), obliterative bronchiolitis, organizing pneumonia, alveolitis allergic, pneumonitis, pulmonary hemorrhage; respiratory distress, pulmonary hypertension, pulmonary edema, pleural effusion, bronchospasm, dyspnea, hypoxia, cough, nasal congestion, nasal discomfort, oropharyngeal pain, rhinorrhea. Skin and Subcutaneous Tissue: toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, palmar-plantar erythrodysesthesia syndrome, radiation recall dermatitis, toxic skin eruption, urticaria, dermatitis, blister, pruritus, erythema, nail disorder, facial swelling, hyperhidrosis, alopecia.
Tumor lysis syndrome: like other cytotoxic drugs, cyclophosphamide may induce tumor-lysis syndrome and hyperuricemia in patients with rapidly growing tumors. Vascular: pulmonary embolism, venous thrombosis, vasculitis, peripheral ischemia, hypertension, hypotension, flushing, hot flush.
Monitoring parameters
- Complete blood count before each dose; urinalysis for hematuria (hemorrhagic cystitis); serum creatinine; sodium (hyponatremia); signs of infection; pregnancy test before treatment. Kidney
- Blood counts
- Urinalysis
- Creatinine and sodium
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Based on its mechanism of action and published reports of effects in pregnant patients or animals, Cyclophosphamide for Injection can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) and Nonclinical Toxicology (13.1)]. Exposure to cyclophosphamide during pregnancy may cause fetal malformations, miscarriage, fetal growth retardation, and toxic effects in the newborn [see Data].
Cyclophosphamide is teratogenic and embryo-fetal toxic in mice, rats, rabbits and monkeys [see Data]. Advise pregnant women and females of reproductive potential of the potential risk to the fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects is 2%-4% and miscarriage is 15%-20% of clinically recognized pregnancies.
Data Human Data Malformations of the skeleton, palate, limbs and eyes as well as miscarriage have been reported after exposure to cyclophosphamide in the first trimester. Fetal growth retardation and toxic effects manifesting in the newborn, including leukopenia, anemia, pancytopenia, severe bone marrow hypoplasia, and gastroenteritis have been reported after exposure to cyclophosphamide.
Animal Data Administration of cyclophosphamide to pregnant mice, rats, rabbits and monkeys during the period of organogenesis at doses at or below the dose in patients based on body surface area resulted in various malformations, which included neural tube defects, limb and digit defects and other skeletal anomalies, cleft lip and palate, and reduced skeletal ossification.
Breastfeeding considerations
Lactation (US label) US FDA label
8.2 Lactation Risk summary Cyclophosphamide is present in breast milk. Neutropenia, thrombocytopenia, low hemoglobin, and diarrhea have been reported in infants breast fed by women treated with cyclophosphamide. Because of the potential for serious adverse reactions in a breastfed child, advise lactating women not to breastfeed during treatment with Cyclophosphamide for Injection and for 1 week after the last dose.
Mechanism of action
12.1 Mechanism of Action The mechanism of action has not been fully characterized. However, cross-linking of tumor cell DNA may be involved. The active alkylating metabolites of cyclophosphamide interfere with the growth of susceptible rapidly proliferating malignant cells.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Cyclophosphamide exposure-response relationships and the time course of pharmacodynamic response have not been fully characterized.
Pharmacokinetics
Key PK parameters
| Half-life | 3 to 12 hours |
|---|---|
| Half-life in kidney failure (ESKD) kidney | 6.5 hours in uremic patients; 3.3 hours during hemodialysis (label) |
| Volume of distribution | 30 to 50 L |
| Protein binding | About 20% (some metabolites over 60%) |
| Metabolism (CYP, transporters) | Hepatic activation (CYP) to 4-hydroxycyclophosphamide |
| Active metabolites | 4-hydroxycyclophosphamide, phosphoramide mustard |
| Renal excretion kidney | 10% to 20% unchanged in urine; mostly metabolites |
| Dialyzability kidney | Yes (37% per 4-hour HD; label) |
Elimination The elimination half-life (t½) of cyclophosphamide ranges from 3 to 12 hours, and clearance (CL) ranges from 4 to 5.6 L/h.
This auto-induction results in an increase in CL, increased formation of active 4-hydroxycyclophosphamide and shortened t½ following multiple doses administered at 12-to 24-hour interval.
Excretion Cyclophosphamide and its metabolites are eliminated by hepatic and renal pathways.
Cyclophosphamide is primarily excreted as metabolites.
Ten to 20% is excreted unchanged in the urine.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Cyclophosphamide is a prodrug. Cyclophosphamide pharmacokinetics are linear over the approved recommended dose range. Distribution The volume of distribution of cyclophosphamide is 30 to 50 L. Cyclophosphamide is approximately 20% protein bound, with no dose dependent changes. Some metabolites are greater than 60% protein bound.
Elimination The elimination half-life (t½) of cyclophosphamide ranges from 3 to 12 hours, and clearance (CL) ranges from 4 to 5.6 L/h. When cyclophosphamide was administered at 4 g/m2 (approximately 2 times the approved recommended dosage) over a 90-minute infusion, concentration-time data demonstrate saturable elimination in parallel with first-order renal elimination.
Metabolism Cyclophosphamide is metabolized by cytochrome P450s including CYP2A6, 2B6, 3A, 2C9, and 2C19. Cyclophosphamide is activated to form 4-hydroxycyclophosphamide, which is in equilibrium with its ring-open tautomer aldophosphamide. 4-hydroxycyclophosphamide and aldophosphamide can undergo oxidation by aldehyde dehydrogenases to form the inactive metabolites 4-ketocyclophosphamide and carboxyphosphamide, respectively.
Aldophosphamide can undergo β-elimination to form active metabolites phosphoramide mustard and acrolein. This spontaneous conversion can be catalyzed by albumin and other proteins. At high doses, the fraction of parent compound cleared by 4-hydroxylation is reduced resulting in non-linear elimination of cyclophosphamide.
Cyclophosphamide appears to induce its own metabolism. This auto-induction results in an increase in CL, increased formation of active 4-hydroxycyclophosphamide and shortened t½ following multiple doses administered at 12-to 24-hour interval. Excretion Cyclophosphamide and its metabolites are eliminated by hepatic and renal pathways.
Cyclophosphamide is primarily excreted as metabolites. Ten to 20% is excreted unchanged in the urine. A small percentage of cyclophosphamide may be eliminated unchanged in bile. Specific Populations Renal Impairment Following one-hour intravenous infusion, cyclophosphamide AUC increased by 38% in patients with CLcr of 25 to 50 mL/min, by 77% in patients with CLcr of 10 to 24 mL/min and by 23% in the hemodialysis group (CLcr of < 10 mL/min) compared to the control group (CLcr≥ 80 mL/min).
Cyclophosphamide is dialyzable. Dialysis clearance averaged 104 mL/min, which is similar to the metabolic clearance of 95 mL/min for cyclophosphamide. A mean of 37% of the administered dose of cyclophosphamide was removed during a 4-hour hemodialysis period. The t½ was 3.3 hours in patients during hemodialysis, a 49% reduction compared to t½ of 6.5 hours in uremic patients.
Hepatic Impairment Cyclophosphamide CL is decreased by 40% (45 ± 8.6 L/kg) and t½ is prolonged by 64% (12.5 ± 1 hours) in patients with hepatic impairment with a mean bilirubin 3.5 mg/dL and mean AST 90 IU/L compared to patients with normal hepatic function (mean bilirubin 0.5 mg/dL, mean AST 10 IU/L).
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Cyclophosphamide 1 g powder Vial | ₱210.00–₱250.00Reference ₱210.00 | per vial | DPRI procurement range |
| Cyclophosphamide 500 mg powder Vial | ₱136.58–₱400.00Reference ₱148.00 | per vial | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Cyclophosphamide |
| PNF listing | Inj.: powder, 200 mg, 500 mg and 1 g vial (IV)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Cyclophosphamide · Hisun Pharmaceuticals USA, Inc. [US FDA-approved label, version 1, October 15, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5bad5bfc-12c0-46a2-8355-1028f108ecbf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- Hisun Pharmaceuticals USA, Inc. (2026). Cyclophosphamide for injection [Prescribing information; US FDA-approved label, ANDA218632, set ID 5bad5bfc-12c0-46a2-8355-1028f108ecbf, version effective October 15, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5bad5bfc-12c0-46a2-8355-1028f108ecbf
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .


